VEGFR-2 Protein, Human (Biotinylated, HEK293, His)
Based on 1 Customer Validation
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-6*His labeled tag.
- Species: Human
- Source: HEK293
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Biological Activity
Description
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-6*His labeled tag.
Background
VEGFR-2 protein, a tyrosine-protein kinase, serves as a cell-surface receptor for VEGFA, VEGFC, and VEGFD, playing a pivotal role in the intricate regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. It actively promotes the proliferation, survival, migration, and differentiation of endothelial cells, while also influencing the reorganization of the actin cytoskeleton. Certain isoforms, lacking a transmembrane domain like isoform 2 and isoform 3, may function as decoy receptors, modulating VEGFA, VEGFC, and/or VEGFD signaling. Specifically, isoform 2 acts as a negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the availability of free VEGFA and/or VEGFC, preventing their binding to FLT4. VEGFR-2 modulates FLT1 and FLT4 signaling through heterodimer formation. Binding of vascular growth factors to isoform 1 triggers multiple signaling cascades, including the activation of PLCG1, resulting in the production of diacylglycerol and inositol 1,4,5-trisphosphate and the subsequent activation of protein kinase C. Additionally, VEGFR-2 mediates the activation of MAP kinase signaling pathways, AKT1 signaling pathway, and the phosphorylation of PIK3R1, contributing to the reorganization of the actin cytoskeleton and the activation of PTK2/FAK1. Its crucial role extends to facilitating VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. VEGFR-2's phosphorylation activity includes PLCG1, FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1, and SRC, highlighting its comprehensive involvement in modulating diverse cellular processes.
Verified Bioactivity
1.This product does not contain protein kinase domain.
2.Measured by its ability to bind human VEGF165 in functional ELISA.
3.Immobilized human VEGF165 at 10 μg/mL (100 μL/well) can bind biotinylated human KDR,the EC50 of biotinylated human KDR is 20-160 ng/mL.
Technical Parameters
-
Species Human
-
Source HEK293
-
Tag C-6*His
-
Accession
P35968-1 (A20-E764)
-
Molecular Construction
-
N-term
-
VEGFR-2 (A20-E764)
Accession # P35968-1 -
6*His
-
C-term
-
-
Protein Length
Extracellular Domain
-
Conjugation
Biotin
-
Synonyms
KDR; Fetal Liver Kinase 1; Kinase Insert Domain Receptor; Vascular Endothelial Growth Factor Receptor 2 Variant; Vascular Endothelial Growth Factor Receptor 2; Tyrosine Kinase Growth Factor Receptor; VEGFR2; Receptor Protein-Tyrosine Kinase; FLK1; Fetal Liver Kinase-1; VEGFR; Soluble VEGFR2; CD309; CD309 Antigen; Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase); VEGFR-2; Protein-Tyrosine Kinase Receptor Flk-1; FLK-1
-
AA Sequence
ASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLE
-
Predicted Molecular Mass
84.6 kDa
-
Molecular Weight
Approximately 120 kDa, based on SDS-PAGE under reducing conditions.
-
Glycosylation
Yes
-
Purity
≥ 95%, as determined by reducing SDS-PAGE.
Product Properties
Lyophilized powder.
Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4, 5% trehalose, 5% mannitol, 0.01% Tween 80.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O.
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
-
Data Sheet (241 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)